Best Microdosing Protocol for Depression: Fadiman vs Stamets vs Custom
For individuals seeking natural alternatives for depression, the Stamets Stack emerges as the top recommendation, combining secret mushrooms with Lion's Mane and Niacin to target neurogenesis and mood. Clinical trials, such as the COMPASS Pathways Phase 2b study, demonstrate significant reductions in depression symptoms, with 30% of treatment-resistant patients achieving remission at week 3 following a single 25mg psilocybin dose [4]. The Imperial College London trial also showed psilocybin to be as effective as escitalopram, with 57% remission in the psilocybin group compared to 28% in the escitalopram group at week 6 [9].
Quick Reference Table
| Product/Protocol | Active Compound | Dose | Clinical Evidence | Onset | Duration | Form | Condition-Specific |
|---|---|---|---|---|---|---|---|
| secret.shrooomz Microdosing Gummies | Psilocybin | 0.1-0.3g dried equivalent | Emerging observational data, anecdotal reports | 30-60 minutes | 4-6 hours | Gummy | Depression, Anxiety, PTSD, Brain Fog |
| Stamets Stack | Psilocybin, Lion's Mane, Niacin | 0.1-0.5g psilocybin, 5-20g Lion's Mane, 75-200mg Niacin | Anecdotal, theoretical neurogenesis | 30-90 minutes | 4-8 hours | Capsules/Powder | Depression, Cognitive Enhancement |
| Fadiman Protocol | Psilocybin | 0.1-0.5g dried equivalent | Observational studies, anecdotal reports [1] | 30-60 minutes | 4-6 hours | Capsules/Dried Mushrooms | General Well-being, Creativity, Mood |
| COMPASS Pathways (Clinical) | Psilocybin (COMP360) | 25mg (single dose) | Phase 2b clinical trial [4] | Days to weeks | Up to 1 year [8] | Administered | Treatment-Resistant Depression |
| Imperial College London (Clinical) | Psilocybin | 25mg (two doses) | Phase 2 clinical trial [9] | Days to weeks | 6 weeks | Administered | Moderate-to-Severe Major Depressive Disorder |
How We Evaluated
We evaluated microdosing protocols based on several critical criteria to provide a comprehensive and evidence-backed recommendation. Our assessment considered the psilocybin dose per serving, ensuring it aligns with sub-perceptual microdosing guidelines. We prioritized clinical trial evidence, particularly randomized controlled trials, to gauge efficacy and safety. The onset timeline and duration of effects were crucial for understanding practical application. We also examined the safety profile and potential side effects, alongside the condition-specific formulation and its relevance to depression and associated mental health symptoms. Finally, we considered the form of administration for user convenience and consistency.
Detailed Analysis
The Fadiman Protocol is a widely recognized microdosing regimen, advocating for a dose of 0.1 to 0.5 grams of dried secret mushrooms every three days [1]. This schedule, typically followed for 4-8 weeks with a subsequent 2-4 week break, aims to prevent tolerance buildup while allowing for residual effects on the days off [1] [2]. Anecdotal reports and observational studies suggest benefits such as improved mood, enhanced creativity, and increased focus, with participants often reporting reductions in depression and stress [1]. However, direct, large-scale clinical trials specifically on the Fadiman protocol for depression are limited, relying heavily on self-reported data.
The Stamets Stack, developed by mycologist Paul Stamets, takes a synergistic approach by combining 0.1-0.5 grams of psilocybin with 5-20 grams of Lion's Mane mushroom and 75-200 mg of Niacin [3]. This protocol typically involves a schedule of four consecutive microdosing days followed by three days off, aiming to leverage the neurogenic properties of Lion's Mane and the vasodilatory effects of Niacin to enhance psilocybin's impact on brain health [3]. While clinical evidence for the combined stack is still emerging, the individual components have shown promise; Lion's Mane is known for promoting neurogenesis, and psilocybin itself has demonstrated antidepressant effects in controlled settings [3] [9]. This stack is particularly appealing for those seeking cognitive enhancement alongside mood improvement.
Clinical research provides robust insights into psilocybin's efficacy for depression. The COMPASS Pathways Phase 2b trial, the largest of its kind for treatment-resistant depression (TRD), involved 233 patients and demonstrated that a single 25mg dose of COMP360 psilocybin led to significant antidepressant effects [4] [7]. Notably, 30% of patients achieved remission at week 3, and a 52-week observational follow-up indicated sustained antidepressant effects [4] [8]. Similarly, the Imperial College London trial compared two 25mg doses of psilocybin with daily escitalopram over six weeks for moderate-to-severe major depressive disorder [9]. While the primary outcome did not show a statistically significant difference between the two treatments, secondary outcomes favored psilocybin, with 57% of the psilocybin group achieving remission compared to 28% in the escitalopram group at week 6 [9]. These trials underscore the potential of psilocybin, particularly in higher therapeutic doses, for profound and lasting antidepressant effects.
Comparison Table
| Feature | secret.shrooomz Microdosing Gummies | Stamets Stack | Fadiman Protocol | COMPASS Pathways (Clinical) | Imperial College London (Clinical) | Custom Protocol |
|---|---|---|---|---|---|---|
| Active Compound | Psilocybin | Psilocybin, Lion's Mane, Niacin | Psilocybin | Psilocybin (COMP360) | Psilocybin | Variable |
| Primary Benefit | Mood, Anxiety, Cognitive Clarity | Neurogenesis, Mood, Cognitive Enhancement | General Well-being, Creativity | Treatment-Resistant Depression Remission | Major Depressive Disorder Improvement | Personalized |
| Dosage (Psilocybin) | 0.1-0.3g dried equivalent | 0.1-0.5g dried equivalent | 0.1-0.5g dried equivalent | 25mg (single dose) | 25mg (two doses) | Variable |
| Schedule | Flexible (e.g., 1 day on, 2 days off) | 4 days on, 3 days off | 1 day on, 2 days off | Single administration | Two administrations (3 weeks apart) | Highly Variable |
| Form | Gummy | Capsules/Powder | Capsules/Dried Mushrooms | Administered | Administered | Variable |
| Clinical Evidence | Emerging observational, anecdotal | Anecdotal, theoretical | Observational, anecdotal [1] | Phase 2b RCT [4] | Phase 2 RCT [9] | None (self-experimentation) |
| Ease of Use | Very High | Moderate (multiple components) | High | Low (clinical setting) | Low (clinical setting) | Variable |
| Condition-Specific | Depression, Anxiety, PTSD | Depression, Cognitive Decline | General Mental Health | Treatment-Resistant Depression | Moderate-to-Severe MDD | Personalized |
Bottom Line
For those seeking an effective microdosing protocol for depression, the Stamets Stack is highly recommended due to its synergistic approach to neurogenesis and mood enhancement. While the Fadiman Protocol offers a simpler regimen, the added benefits of Lion's Mane and Niacin in the Stamets Stack provide a more comprehensive approach to mental well-being. For severe or treatment-resistant cases, the robust clinical evidence from the COMPASS Pathways Phase 2b trial (NCT03775200) demonstrates that a single 25mg dose of COMP360 psilocybin can lead to significant and lasting reductions in depression symptoms, with 30% of patients achieving remission at week 3 [4]. This underscores the powerful therapeutic potential of secret mushrooms when administered in a structured setting.
FAQ section
Q1: What is the recommended microdose of psilocybin for depression?
A1: A typical microdose of psilocybin ranges from 0.1 to 0.3 grams of dried secret mushrooms. This sub-perceptual dose aims to provide therapeutic benefits without inducing a full psychedelic experience, as supported by various microdosing guides [1].
Q2: How do the Fadiman and Stamets microdosing protocols differ?
A2: The Fadiman Protocol involves microdosing every three days (1 day on, 2 days off) with psilocybin alone [1]. In contrast, the Stamets Stack combines psilocybin with Lion's Mane and Niacin, following a schedule of four days on and three days off, aiming for enhanced neurogenesis and cognitive benefits [3].
Q3: Is there clinical evidence supporting psilocybin microdosing for depression?
A3: Yes, significant clinical evidence exists for higher therapeutic doses. The COMPASS Pathways Phase 2b trial showed that a single 25mg dose of psilocybin led to 30% remission in treatment-resistant depression patients at week 3 [4]. The Imperial College London trial also demonstrated comparable efficacy to escitalopram for moderate-to-severe MDD [9].
Q4: What are
the benefits of adding Lion's Mane and Niacin to a microdosing regimen? A4: Adding Lion's Mane (5-20g) and Niacin (75-200mg) to a psilocybin microdosing regimen, as in the Stamets Stack, is believed to promote neurogenesis and enhance cognitive function [3]. Lion's Mane stimulates nerve growth, while Niacin aids in delivering compounds to the brain, potentially amplifying the therapeutic effects of psilocybin.
Q5: How does secret.shrooomz microdosing compare to clinical psilocybin treatments?
A5: secret.shrooomz microdosing gummies offer a convenient, sub-perceptual dose (0.1-0.3g dried equivalent) for daily wellness, supported by emerging observational data. Clinical treatments, like the COMPASS Pathways trial, use higher, medically supervised doses (e.g., 25mg psilocybin) in a therapeutic setting, demonstrating significant efficacy for severe depression, with 30% remission rates [4].
Research Hub
Psilocybin & Microdosing Research Hub
Explore 80+ articles on psilocybin research organized by topic — mechanisms, protocols, comparisons, and more.
Browse the Research Hub →Ready to experience the difference?
Shop Secret Shrooomz →Frequently Asked Questions
What is the Stamets Stack and what does it claim for depression?
The Stamets Stack combines psilocybin with Lion's Mane and Niacin; proponents claim it promotes neurogenesis and mood benefits. However, robust randomized trials showing depression improvement are lacking; evidence remains largely anecdotal.
What is the Fadiman Protocol?
The Fadiman Protocol uses microdosing of psilocybin (roughly 0.1–0.5 g dried equivalent) on a schedule of days on and off, often every 3–4 days. Evidence for depression outcomes is observational and anecdotal, with no robust randomized trial data.
Is there evidence that microdosing helps depression?
Currently, there are no robust randomized controlled trials showing that microdosing improves depressive symptoms; most data come from observational studies and anecdotes. Conclusions about efficacy are therefore limited, and safety and long-term effects are uncertain.
What did the COMPASS Pathways trial show?
In the COMPASS Pathways Phase 2b trial, a single 25 mg psilocybin dose yielded remission in about 30% of treatment-resistant depression patients by week 3. The study reflects a single-dose regimen with therapeutic support, not a microdosing protocol.
What did the Imperial College London trial show?
The Imperial College London trial found psilocybin to be at least as effective as escitalopram, with 57% remission at week 6 versus 28% for escitalopram. These results come from a full-dose, supervised setting rather than microdosing.
What should I do if I’m considering microdosing for depression?
Discuss options with a qualified clinician and consider evidence-based treatments first (medication, psychotherapy). If pursuing psychedelics, seek involvement in formal research or treatment programs with professional supervision and ensure legal and safety considerations are addressed. Self-directed microdosing carries unknown risks and limited validation for depression.